interleukin-7 gene-modified autologous tumor cells

Interleukin-7 gene-modified autologous tumor cells are an investigational form of personalized cancer immunotherapy in which a patient's own tumor cells are collected, then genetically engineered ex vivo to express the cytokine interleukin-7 (IL-7) before being rendered replication-defective and re-administered as a therapeutic vaccine. The expressed IL-7 enhances T cell survival, expansion, and anti-tumor immune responses. Clinical trials have explored their use particularly in advanced or metastatic solid tumors, such as renal cell carcinoma and metastatic carcinoma, aiming to stimulate robust anti-tumor immunity and promote immune-mediated tumor control. Reported effects include immune activation with increases in CD3+, CD8+, and CD56+ lymphocytes, and induction of a TH2-predominant immune response in some settings. These vaccines have generally demonstrated favorable safety profiles in early-phase clinical studies[4].